Hepatitis Monthly

Published by: Kowsar

Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents

Niloofar Naderi 1 , Ghazal Masoudi 2 , Bita Behnava 3 , Seyed Moayed Alavian 3 , Soyar Sari 2 , Ali Anvar 1 , Alireza Azizi Saraji 1 , Ali Namvar 1 , * and Azam Bolhassani 4 , **
Authors Information
1 Iranian Comprehensive Hemophilia Care Center, Tehran, Iran
2 Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
3 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
4 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: 18 (12); e83337
  • Published Online: December 30, 2018
  • Article Type: Research Article
  • Received: August 14, 2018
  • Revised: November 16, 2018
  • Accepted: November 19, 2018
  • DOI: 10.5812/hepatmon.83337

To Cite: Naderi N, Masoudi G, Behnava B, Alavian S M, Sari S, et al. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents, Hepat Mon. Online ahead of Print ; 18(12):e83337. doi: 10.5812/hepatmon.83337.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Pawlowska M, Domagalski K. Risk of HBV reactivation in patients infected with HBV/HCV treated with DAA. Hepat Mon. 2017;17(8). e12317. doi: 10.5812/hepatmon.12317.
  • 2. Mandour M, Nemr N, Shehata A, Kishk R, Badran D, Hawass N. Occult HBV infection status among chronic hepatitis C and hemodialysis patients in Northeastern Egypt: Regional and national overview. Rev Soc Bras Med Trop. 2015;48(3):258-64. doi: 10.1590/0037-8682-0037-2015. [PubMed: 26108002].
  • 3. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599]. [PubMed Central: PMC4303918].
  • 4. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: Considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55 Suppl 1:S10-5. doi: 10.1093/cid/cis361. [PubMed: 22715208].
  • 5. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. [PubMed: 26231459].
  • 6. Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The relevance of hepatitis B core antibody: A review of new issues. Am J Gastroenterol. 2017;112(12):1780-8. doi: 10.1038/ajg.2017.397. [PubMed: 29087395].
  • 7. Saffioti F, Raimondo G. What do we know about occult hepatitis B virus infection? APMB. 2017;105(2):1-13. doi: 10.6092/1828-6550/APMB.105.2.2017.SD2.
  • 8. Calvaruso V, Craxi A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol. 2017;67(5):898-901. doi: 10.1016/j.jhep.2017.08.017. [PubMed: 28864279].
  • 9. Wahle RC, Perez RM, Pereira PF, Oliveira EM, Emori CT, Uehara SN, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis. 2015;19(5):533-7. doi: 10.1016/j.bjid.2015.04.003. [PubMed: 25997784].
  • 10. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: Epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221-8. [PubMed: 25830779]. [PubMed Central: PMC4367211].
  • 11. Mucke MM, Backus LI, Mucke VT, Coppola N, Preda CM, Yeh ML, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172-80. doi: 10.1016/S2468-1253(18)30002-5. [PubMed: 29371017].
  • 12. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170-80. doi: 10.1093/annonc/mdq583. [PubMed: 21115603]. [PubMed Central: PMC3082161].
  • 13. Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: A systematic review and meta-analysis. Ann Intern Med. 2016;164(1):30-40. doi: 10.7326/M15-1121. [PubMed: 26595058].
  • 14. Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int. 2015;35 Suppl 1:35-43. doi: 10.1111/liv.12712. [PubMed: 25529086].
  • 15. Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol. 2005;4(2):100-6. [PubMed: 16010242].
  • 16. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, et al. Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. Hepatology. 2009;50(1):46-55. doi: 10.1002/hep.22951. [PubMed: 19333911].
  • 17. Tramuto F, Maida CM, Colomba GM, Di Carlo P, Vitale F. Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int. 2013;2013:859583. doi: 10.1155/2013/859583. [PubMed: 24063015]. [PubMed Central: PMC3770005].
  • 18. Oliveira MP, Lemes PS, Matos MA, Del-Rios NH, Carneiro MA, Silva AM, et al. Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil. J Med Virol. 2016;88(7):1222-9. doi: 10.1002/jmv.24462. [PubMed: 27061406].
  • 19. Omar HH, Taha SA, Hassan WH, Omar HH. Impact of schistosomiasis on increase incidence of occult hepatitis B in chronic hepatitis C patients in Egypt. J Infect Public Health. 2017;10(6):761-5. doi: 10.1016/j.jiph.2016.11.010. [PubMed: 28196636].
  • 20. McClary H, Koch R, Chisari FV, Guidotti LG. Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med. 2000;192(2):289-94. [PubMed: 10899915]. [PubMed Central: PMC2193253].
  • 21. Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66(1):13-26. doi: 10.1002/hep.29109. [PubMed: 28195337].
  • 22. Gish RG. HBV/HCV coinfection and possible reactivation of HBV following DAA use. Gastroenterol Hepatol (N Y). 2017;13(5):292-5. [PubMed: 28656026]. [PubMed Central: PMC5479342].
  • 23. Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: A review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166(11):792-8. doi: 10.7326/M17-0377. [PubMed: 28437794].
  • 24. Ma K, Shokoohi S, Reau N. Reactivation of occult HBV infection in patients cured of HCV with direct-acting antivirals. Curr Treat Option Infect Dis. 2017;9(4):380-8. doi: 10.1007/s40506-017-0134-8.
  • 25. Suda T, Shimakami T, Shirasaki T, Yamashita T, Mizukoshi E, Honda M, et al. Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents. J Hepatol. 2017;67(5):1108-11. doi: 10.1016/j.jhep.2017.07.014. [PubMed: 28739112].
  • 26. Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2013;22(9):1107-21. doi: 10.1517/13543784.2013.806482. [PubMed: 23735127].
  • 27. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335-74. doi: 10.1002/hep.22759. [PubMed: 19330875].
  • 28. Liu CH, Liu CJ, Su TH, Fang YJ, Yang HC, Chen PJ, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis. 2017;4(1):ofx028. doi: 10.1093/ofid/ofx028. [PubMed: 28480296]. [PubMed Central: PMC5414056].
  • 29. Dagur PK, McCoy JP Jr. Collection, storage, and preparation of human blood cells. Curr Protoc Cytom. 2015;73:5 1 1-16. doi: 10.1002/0471142956.cy0501s73. [PubMed: 26132177]. [PubMed Central: PMC4524540].
  • 30. Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32(10):1754-62. doi: 10.1111/jgh.13771. [PubMed: 28230928].
  • 31. Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol. 2017;23(24):4317-23. doi: 10.3748/wjg.v23.i24.4317. [PubMed: 28706414]. [PubMed Central: PMC5487495].
  • 32. Ranjbar M, Dadkhah M, Bokharaei Salim F, Daneshbodi M, Savaj S, Keyvani H. The prevalence of occult HBV infection among hemodialysis patients of Tehran, Iran. Mod Care J. 2017;14(4). doi: 10.5812/modernc.65546.
  • 33. Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16(6):651-72. doi: 10.1080/14740338.2017.1325869. [PubMed: 28471314]. [PubMed Central: PMC5589072].
  • 34. Huang R, Yan X, Xia J, Wang J, Wu C. Letter: Hepatitis B virus reactivation in patients with chronic hepatitis C during direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2017;45(12):1558. doi: 10.1111/apt.14080. [PubMed: 28503862].
  • 35. Fabbri G, Mastrorosa I, Vergori A, Mazzotta V, Pinnetti C, Grisetti S, et al. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: A case report and review of the literature. BMC Infect Dis. 2017;17(1):182. doi: 10.1186/s12879-017-2287-y. [PubMed: 28249574]. [PubMed Central: PMC5333431].
  • 36. Londono MC, Lens S, Marino Z, Bonacci M, Ariza X, Broquetas T, et al. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther. 2017;45(8):1156-61. doi: 10.1111/apt.13985. [PubMed: 28206681].
  • 37. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132-6. doi: 10.1016/j.cgh.2016.06.023. [PubMed: 27392759].
  • 38. Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018;25(1):72-9. doi: 10.1111/jvh.12754. [PubMed: 28703895].
  • 39. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538-45. doi: 10.1002/hep.26400. [PubMed: 23505059]. [PubMed Central: PMC3729715].
  • 40. Mekky MA, Nasr AM, Saleh MA, Wasif NK, Khalaf M, Aboalam H, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol. 2013;14(4):143-7. doi: 10.1016/j.ajg.2013.11.003. [PubMed: 24433642].
  • 41. Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, et al. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers. Neth J Med. 2008;66(5):191-5. [PubMed: 18490796].
  • 42. Ozaras R, Mete B, Tabak F. Occult hepatitis B and risk of reactivation after hepatitis C treatment with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15(4):605. doi: 10.1016/j.cgh.2016.11.030. [PubMed: 27923721].
  • 43. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, et al. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. J Hepatol. 2017;67(5):1106-8. doi: 10.1016/j.jhep.2017.04.008. [PubMed: 28438688].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments